These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 15167099)

  • 1. Pharmacokinetics and safety of the MRI contrast agent gadoversetamide injection (OptiMARK) in healthy pediatric subjects.
    Baker JF; Kratz LC; Stevens GR; Wible JH
    Invest Radiol; 2004 Jun; 39(6):334-9. PubMed ID: 15167099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of gadoversetamide injection, a gadolinium-based contrast agent, in pediatric patients.
    Wible JH; Tata PN; Napoli AM; Lowe LH; Kearns GL
    Magn Reson Imaging; 2009 May; 27(4):512-8. PubMed ID: 18814985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics, safety, and tolerability of gadoversetamide injection (OptiMARK) in subjects with central nervous system or liver pathology and varying degrees of renal function.
    Swan SK; Baker JF; Free R; Tucker RM; Barron B; Barr R; Seltzer S; Gazelle GS; Maravilla KR; Barr W; Stevens GR; Lambrecht LJ; Pierro JA
    J Magn Reson Imaging; 1999 Feb; 9(2):317-21. PubMed ID: 10077031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The safety and efficacy of neuroimaging with gadoversetamide injection in pediatric patients.
    Lowe LH; Kearns GL; Wible JH
    Curr Med Res Opin; 2006 Dec; 22(12):2515-24. PubMed ID: 17166334
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and safety of gadobutrol-enhanced magnetic resonance imaging in pediatric patients.
    Hahn G; Sorge I; Gruhn B; Glutig K; Hirsch W; Bhargava R; Furtner J; Born M; Schröder C; Ahlström H; Kaiser S; Moritz JD; Kunze CW; Shroff M; Stokland E; Trnkova ZJ; Schultze-Mosgau M; Reif S; Bacher-Stier C; Mentzel HJ
    Invest Radiol; 2009 Dec; 44(12):776-83. PubMed ID: 19858730
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toxicological assessment of gadoversetamide injection (OptiMARK), a new contrast-enhancement agent for use in magnetic resonance imaging.
    Wible JH; Troup CM; Hynes MR; Galen KP; MacDonald JR; Barco SJ; Wojdyla JK; Periasamy MP; Adams MD
    Invest Radiol; 2001 Jul; 36(7):401-12. PubMed ID: 11496095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and pharmacokinetic profile of gadobenate dimeglumine in subjects with renal impairment.
    Swan SK; Lambrecht LJ; Townsend R; Davies BE; McCloud S; Parker JR; Bensel K; LaFrance ND
    Invest Radiol; 1999 Jul; 34(7):443-8. PubMed ID: 10399633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety assessment of gadoversetamide (OptiMARK) administered by power injector.
    Abdou N; Napoli AM; Hynes MR; Allen JC; Wible JH
    J Magn Reson Imaging; 2004 Jan; 19(1):133-40. PubMed ID: 14696230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics, dose proportionality, and tolerability of gadobutrol after single intravenous injection in healthy volunteers.
    Staks T; Schuhmann-Giampieri G; Frenzel T; Weinmann HJ; Lange L; Platzek J
    Invest Radiol; 1994 Jul; 29(7):709-15. PubMed ID: 7960618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and Safety of Macrocyclic Gadobutrol in Children Aged Younger Than 2 Years Including Term Newborns in Comparison to Older Populations.
    Kunze C; Mentzel HJ; Krishnamurthy R; Fleck R; Stenzel M; Bhargava R; Burrowes D; Sutter G; Schultze-Mosgau M; Santiuste M; Hahn G
    Invest Radiol; 2016 Jan; 51(1):50-7. PubMed ID: 26340504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Pharmacokinetics, Efficacy, and Safety Study of Gadoterate Meglumine in Pediatric Subjects Aged Younger Than 2 Years.
    Scala M; Koob M; de Buttet S; Bourrinet P; Felices M; Jurkiewicz E
    Invest Radiol; 2018 Feb; 53(2):70-79. PubMed ID: 28906338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multicenter, randomized, double-blind study to evaluate the safety, tolerability, and efficacy of OptiMARK (gadoversetamide injection) compared with Magnevist (gadopentetate dimeglumine) in patients with liver pathology: results of a Phase III clinical trial.
    Rubin DL; Desser TS; Semelka R; Brown J; Nghiem HV; Stevens WR; Bluemke D; Nelson R; Fultz P; Reimer P; Ho V; Kristy RM; Pierro JA
    J Magn Reson Imaging; 1999 Feb; 9(2):240-50. PubMed ID: 10077020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic behavior of gadoteridol injection.
    McLachlan SJ; Eaton S; De Simone DN
    Invest Radiol; 1992 Aug; 27 Suppl 1():S12-5. PubMed ID: 1506147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular effects caused by rapid administration of gadoversetamide injection in anesthetized dogs.
    Wible JH; Galen KP; Wojdyla JK
    Invest Radiol; 2001 May; 36(5):292-8. PubMed ID: 11394361
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of gadobenate dimeglumine in children 2 to 5 years of age undergoing MRI of the central nervous system.
    Pirovano G; Kirchin MA; Lorusso V; Patel R; Shen N
    J Magn Reson Imaging; 2015 Apr; 41(4):1096-103. PubMed ID: 24807269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I clinical trial with gadodiamide injection, a nonionic magnetic resonance imaging enhancement agent.
    VanWagoner M; O'Toole M; Worah D; Leese PT; Quay SC
    Invest Radiol; 1991 Nov; 26(11):980-6. PubMed ID: 1743922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Measurement of serum calcium concentration after administration of gadoversetamide in dogs.
    Wible JH; Hynes MR
    Radiology; 2004 Oct; 233(1):158-64. PubMed ID: 15454620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety of gadoversetamide in patients with acute and chronic myocardial infarction.
    Huber S; Muthupillai R; Cheong B; Wible JH; Shah D; Woodard P; Grothues F; Mahrholdt H; Rochitte CE; Masoli O; Kim RJ; Schwaiger CM; Fuisz A; Kramer C; van Rossum AC; Biederman R; Lombardi M; Martin E; Kevorkian R; Flamm SD
    J Magn Reson Imaging; 2008 Dec; 28(6):1368-78. PubMed ID: 19025944
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in signal intensity in the dentate nucleus at unenhanced T1-weighted magnetic resonance imaging depending on class of previously used gadolinium-based contrast agent.
    Kasper E; Schemuth HP; Horry S; Kinner S
    Pediatr Radiol; 2018 May; 48(5):686-693. PubMed ID: 29417165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of 1M gadobutrol in patients with chronic renal failure.
    Tombach B; Bremer C; Reimer P; Schaefer RM; Ebert W; Geens V; Heindel W
    Invest Radiol; 2000 Jan; 35(1):35-40. PubMed ID: 10639034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.